Edition:
India

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

19.05USD
2:29am IST
Change (% chg)

$-0.25 (-1.30%)
Prev Close
$19.30
Open
$19.20
Day's High
$19.70
Day's Low
$18.80
Volume
266,937
Avg. Vol
235,008
52-wk High
$25.15
52-wk Low
$11.93

Latest Key Developments (Source: Significant Developments)

Orchard Therapeutics appoints Frank Thomas as CFO
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Orchard Therapeutics: :ORCHARD THERAPEUTICS APPOINTS FRANK THOMAS AS CHIEF FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER​.ORCHARD THERAPEUTICS SAYS ‍UNTIL RECENTLY THOMAS SERVED AS PRESIDENT AND CHIEF OPERATING OFFICER OF AMAG PHARMACEUTICALS​.  Full Article

AMAG Pharmaceuticals Sees Q4 2017 Revenue $156 Mln to $163 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 GUIDANCE.SEES Q4 2017 REVENUE $156 MILLION TO $163 MILLION.SEES FY 2017 REVENUE $613 MILLION TO $620 MILLION.SEES FY 2017 REVENUE UP 15 PERCENT.SEES Q4 2017 REVENUE UP ABOUT 5 PERCENT.- ‍FOR Q4 OF 2017, AMAG EXPECTS AN OPERATING LOSS OF BETWEEN $6 MILLION AND $16 MILLION​.- ‍EXPECTS 2017 TOTAL GAAP REVENUE TO BE BETWEEN $607 MILLION AND $614 MILLION​.SEES ‍ 2017 OPERATING LOSS OF BETWEEN $292 MILLION AND $302 MILLION (DUE PRIMARILY TO A Q3 NON-CASH ACCOUNTING CHARGE)​.SEES ‍2018 TOTAL GAAP REVENUE $500 MILLION - $560 MILLION​.SEES ‍2018 GAAP OPERATING LOSS $147 MILLION - $117 MILLION​.Q4 REVENUE VIEW $161.1 MILLION -- THOMSON REUTERS I/B/E/S.FY2017 REVENUE VIEW $616.0 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $504.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Palatin Technologies signs licensing agreement with Kwangdong Pharma
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Palatin Technologies :Palatin Technologies announces signing of licensing agreement with Kwangdong Pharmaceutical for Republic of Korea.A NDA anticipated to be filed with U.S. Food and Drug Administration in Q1 of calendar year 2018​.  Full Article

Amag Pharmaceuticals Q3 loss per share $4.31
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Amag Pharmaceuticals Inc :Amag Pharmaceuticals announces third quarter 2017 financial results and business highlights.Q3 loss per share $4.31.Q3 earnings per share view $0.18 -- Thomson Reuters I/B/E/S.Q3 revenue $153.7 million versus I/B/E/S view $168.5 million.Amag Pharmaceuticals Inc - ‍co has updated 2017 Makena revenue guidance to between $385 million and $395 million​.  Full Article

AMAG Pharmaceuticals Inc says announced results from its definitive pharmacokinetic study
Thursday, 2 Feb 2017 

AMAG Pharmaceuticals Inc : AMAG Pharmaceuticals Inc says announced results from its definitive pharmacokinetic (PK) study . AMAG Pharmaceuticals Inc says met primary study objective of demonstrating bioequivalence on measure of AUC .AMAG Pharmaceuticals Inc says plan to submit a supplemental new drug application to FDA for Makena subcutaneous auto-injector in Q2 of 2017.  Full Article

Amag Pharmaceuticals qtrly loss per share $0.02
Tuesday, 9 Aug 2016 

Amag Pharmaceuticals Inc : Amag Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Qtrly loss per share $0.02 . Q2 earnings per share view $1.20, revenue view $128.5 million -- Thomson Reuters I/B/E/S . Fy2016 revenue view $533.8 million -- Thomson Reuters I/B/E/S . Total gaap quarterly product and service revenues increased approximately 50% to $127 million . Amag pharmaceuticals inc says total product and service revenue for q2 of 2016 increased approximately 50% to $127.4 million . Sees fy 2016 gaap total revenue $503 million - $553 million . Sees fy 2016 non gaap total revenue $520 - $570 million .Sees fy 2016 gaap net income $0 - $30 million ; sees fy 2016 non gaap net income $195 - $225 million.  Full Article

Amag Pharma- FDA provides manufacturing update on Makena
Friday, 22 Jul 2016 

Amag Pharmaceuticals Inc : Notified by FDA that prior approval supplement for coldstream labs approved for manufacture of preservative-free formulation of Makena .Approval provides company with an alternative manufacturer for single-dose formulation of Makena.  Full Article

AMAG Pharmaceuticals Inc gives FY 2016 guidance
Tuesday, 3 May 2016 

AMAG Pharmaceuticals Inc:Expects FY 2016 non-GAAP total product revenue of $520 - $570 million.Expects FY 2016 non-GAAP adjusted EBITDA of $255- $285 million.Expects FY 2016 non-GAAP net income of $195- $225 million.  Full Article

BRIEF-AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector

* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN